Day: December 7, 2022

NGM707 was generally well tolerated to the highest dose evaluated (1800 mg) in the monotherapy escalation; maximum tolerated dose was not reached Linear pharmacokinetics (PK) was observed at doses ≥200 mg, and analysis of peripheral immune cells demonstrated dose-dependent receptor occupancy (RO), with doses ≥200 mg maintaining full ILT2 and ILT4 RO for the entire dosing interval to date Potential proof-of-mechanism (myeloid reprogramming) was observed in peripheral blood and tumor biopsies Early signals of anti-tumor activity demonstrated across multiple tumor types. Of 24 response-evaluable patients as of November 23, 2022, best overall responses are partial response in 1 patient, stable disease in 6 patients and non-complete response/non-progressive disease in 1 patient NGM707, ILT2/ILT4 antagonist antibody, is the most advanced of...

KANSAS CITY, Mo., Dec. 07, 2022 (GLOBE NEWSWIRE) — Newsweek announced today that H&R Block (NYSE: HRB) is among its 2023 “America’s Most Responsible Companies.” This annual recognition is given to organizations that have demonstrated excellence in the areas of environmental, social, and corporate governance responsibility. “H&R Block has had a long-term commitment to people, community and the planet, and in many ways, we’re just getting started,” said Jeff Jones, President and CEO of H&R Block. “Thank you to our associates, tax pros, and franchisees for giving back to their communities, living out our Purpose, and doing their part to be good corporate citizens.” Companies were selected based on key performance indicators in three areas of their annual ESG reports, along with consumer survey results about brand responsibility....

Conference Call and Webcast Scheduled for December 13th, 8:30 AM ET New York, NY, Dec. 07, 2022 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report first quarter fiscal 2023 financial and operating results after the market close on Monday, December 12, 2022. The Form 10-Q filing will be followed by a live audio webcast and conference call the next day at 8:30 AM ET. To participate in the conference call, please dial the following numbers prior to the start of the call or click the webcast link below to participate over the internet: Tuesday, December 13th @ 8:30 am ETDomestic: 1-877-407-0792International: 1-201-689-8263Conference ID: 13734855Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1588117&tp_key=b07d7a641cA replay...

Presentation on Thursday, December 8th, 2022 at 1:00 PM ET CAVE CREEK, AZ, Dec. 07, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Endexx Corporation (OTC:EDXC), a provider of innovative, plant-based, and sustainable health and skincare products, announced today that it will be presenting virtually at the upcoming Sequire Virtual Small Cap Conference on Thursday, December 8th, at 1:00 PM EST. Todd Davis, CEO of Endexx, will be giving the presentation. Endexx CEO Todd Davis stated, “Endexx is accelerating into its revenue growth phase, expanding to over 8000 mass retailers in 2022 and rapidly expanding internationally with its new acquisition of HYLA. HYLA in its first two months in Endexx has generated new orders exceeding 6 million in sales with prospects of adding significantly more revenues in 2023.” Davis concluded, “The dynamics...

BALTIMORE, Dec. 07, 2022 (GLOBE NEWSWIRE) — Adams Natural Resources Fund, Inc. (NYSE: PEO) has determined that $21.40 per share is the issue price for the closed-end fund’s year-end distribution to shareholders who have elected to receive all or a portion of the distribution in the form of stock. This price is the mean between the high and low sales prices of the Fund’s stock on the New York Stock Exchange on December 7, 2022. The shares of common stock will be issued in connection with payment of the $1.33 year-end distribution, consisting of $0.53 in net investment income and $0.80 in net realized capital gains. The year-end distribution is payable on December 16, 2022. The Fund has committed to distributing each year an amount equal to at least 6% of the Fund’s trailing 12-month average month-end market price. This year, the...

BALTIMORE, Dec. 07, 2022 (GLOBE NEWSWIRE) — Adams Diversified Equity Fund, Inc. (NYSE: ADX) has determined that $15.01 per share is the issue price for the closed-end fund’s year-end distribution to shareholders who have elected to receive all or a portion of the distribution in the form of stock. This price is the mean between the high and low sales prices of the Fund’s stock on the New York Stock Exchange on December 7, 2022. The shares of common stock will be issued in connection with payment of the $0.92 year-end distribution, consisting of $0.06 in net investment income and $0.86 in net realized capital gains. The year-end distribution is payable on December 21, 2022. The Fund has committed to distributing each year an amount equal to at least 6% of the Fund’s trailing 12-month average month-end market price. This year, the...

MONACO, Dec. 07, 2022 (GLOBE NEWSWIRE) — Scorpio Tankers Inc. (NYSE:STNG) (“Scorpio Tankers,” or the “Company”) announced today that on Wednesday, December 14, 2022, the Company plans to issue a market update, including Q4 2022 daily TCE revenues, and host a conference call at 8:30am Eastern Standard Time and 2:30pm Central European Time. The Conference call details are as follows: Date: Wednesday, December 14, 2022Time: 8:30 AM Eastern Standard Time and 2:30 PM Central European Time The conference call will be available over the internet, through the Scorpio Tankers Inc. website www.scorpiotankers.com and the webcast link: https://edge.media-server.com/mmc/p/vxcy9q9s Participants for the live webcast should register on the website approximately 10 minutes prior to the start of the webcast. The conference will also be available...

RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2022 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided initial results from a 24 patient Phase 2 mechanism of action (MOA) trial showing favorable alterations in the tumor microenvironment from a single dose of trilaciclib monotherapy as measured by increases in the proportions of CD8+ T cells compared to T regulatory cells (Tregs) in patients with early-stage triple negative breast cancer (TNBC). These initial study results are being presented in a poster session at the annual San Antonio Breast Cancer Symposium (SABCS), December 6 – 10, 2022. “The initial goal of this trial is to confirm our understanding of the trilaciclib immune mechanism by evaluating changes in the tumor immune microenvironment in a clinical setting following...

TORONTO, Dec. 07, 2022 (GLOBE NEWSWIRE) — Green Shift Commodities Ltd. (TSXV: GCOM), (“Green Shift” or the “Company”) is pleased to announce its intention to complete a non-brokered private placement on a best efforts basis of units of the Company (the “Units”) at a price of $0.15 per Unit (the “Issue Price”) for minimum gross proceeds to the Company of $1,500,000 and maximum gross proceeds equal to the maximum amount that may be issued pursuant to the Listed Issuer Financing Exemption, as defined below (the “Offering”). The Offering is being completed pursuant to the Listed Issuer Financing Exemption and accordingly the securities issued in the Offering will not be subject to a hold period pursuant to applicable Canadian securities laws. Each Unit will consist of one common share in the capital of the Company (each, a “Common...